Resverlogix Corp. (TSE:RVX – Get Free Report)’s stock price reached a new 52-week low on Monday . The stock traded as low as C$0.04 and last traded at C$0.04, with a volume of 1525 shares trading hands. The stock had previously closed at C$0.05.
Resverlogix Price Performance
The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04. The firm has a market capitalization of C$9.90 million, a price-to-earnings ratio of -2.48 and a beta of 0.71. The business’s fifty day simple moving average is C$0.05 and its 200 day simple moving average is C$0.06.
About Resverlogix
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- Want to Profit on the Downtrend? Downtrends, Explained.
- Energy Transfer: Powering Data With Dividends and Diversification
- There Are Different Types of Stock To Invest In
- Qualcomm Stock Is Coiling for a Breakout
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
